Celiac.com Sponsor (A1):



Celiac.com Sponsor (A1):


  • Join Our Community!

    Ask us a question in our celiac / gluten-free forum.

  • Scott Adams

    How and When to Use a Gluten Contamination Elimination Diet for Patients with Non-Responsive Celiac Disease

    Scott Adams
    1 1
    Reviewed and edited by a celiac disease expert.

      A gluten contamination elimination diet can help diagnose and treat non-responsive celiac disease.


    Cooking at the farmers market. Image: CC BY 2.0--gmtbillings
    Caption: Cooking at the farmers market. Image: CC BY 2.0--gmtbillings

    Celiac.com 05/18/2020 - Most people with celiac disease see a major improvement in the weeks and months after they begin a gluten-free diet. Most celiac patients on a gluten-free diet experience full gut healing within the first few months, and nearly all of them within 12-18 months. However, nearly one in three celiac patients may show adverse signs, symptoms or persistent small intestinal damage after one year on a gluten-free diet. To properly diagnose and treat these patients, they must be assessed for other common GI problems, and for their celiac disease status. 

    A team of researchers recently set out to develop guidelines for the indications and use of the gluten contamination elimination diet for patients with non-responsive celiac disease. The research team included Maureen M. Leonard, Pamela Cureton, and Alessio Fasano, who are variously affiliated with the Center for Celiac Research, Mucosal Immunology and Biology Research Center, Massachusetts General Hospital and Division of Pediatric Gastroenterology and Nutrition, Massachusetts General Hospital for Children, Boston, MA, USA, and the Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA.



    Celiac.com Sponsor (A12):




    In their paper titled, Indications and Use of the Gluten Contamination Elimination Diet for Patients with Non-Responsive Celiac Disease, they offer a method for assessing patients with celiac disease with ongoing symptoms, elevated serology, and or villous atrophy, even on a gluten-free diet. 

    The team details methods for diagnosing, and distinguishing between, non-responsive and refractory celiac disease. Lastly, the team describes the range of conditions for employing the gluten contamination elimination diet, and offers guidance for clinicians to use the diet as needed for their non-responsive celiac patients who meet the criteria.

    Since a significant number of people with celiac disease fail to improve on a gluten-free diet, these guidelines will be helpful in spotting and treating these patients. Do you or a loved one suffer from non-responsive celiac disease? Share your story in the comments below.

    Read more in Nutrients, Volume 9  Issue 10

    Edited by Scott Adams

    1 1

    User Feedback

    Recommended Comments

    There are no comments to display.



    Guest
    This is now closed for further comments

  • About Me

    Scott Adams was diagnosed with celiac disease in 1994, and, due to the nearly total lack of information available at that time, was forced to become an expert on the disease in order to recover. In 1995 he launched the site that later became Celiac.com to help as many people as possible with celiac disease get diagnosed so they can begin to live happy, healthy gluten-free lives.  He is co-author of the book Cereal Killers, and founder and publisher of the (formerly paper) newsletter Journal of Gluten Sensitivity. In 1998 he founded The Gluten-Free Mall which he sold in 2014. Celiac.com does not sell any products, and is 100% advertiser supported.


  • Celiac.com Sponsor (A17):
    Celiac.com Sponsor (A17):





    Celiac.com Sponsors (A17):




  • Related Articles

    Jefferson Adams
    Celiac.com 04/07/2014 - Histologically non-responsive celiac disease (NRCD) is a potentially serious condition found in celiac disease patients who suffer persistent villous atrophy despite following a gluten-free diet (GFD).
    Currently, the only way to monitor patient progress rely on invasive and costly serial duodenal biopsies. Looking for better options, a team of researchers recently set out to identify antibody biomarkers for celiac disease patients that do not respond to traditional therapy.
    The research team included B. N. Spatola, K. Kaukinen, P. Collin, M. Mäki, M. F. Kagnoff, and P. S. Daugherty. They are affiliated with the Department ...

    Jefferson Adams
    Celiac.com 02/25/2019 - Even when following a gluten-free diet, many people with celiac disease occasionally ingest small amounts of gluten in food. However, researchers don’t have much good data on how that plays out in real life. Testing patient stool and urine is an excellent way to measure the frequency of gluten exposure in celiac patients who are on a gluten-free diet. To get a better picture, a team of researchers recently set out to explore the pattern of fecal and urinary excretion of gluten immunogenic peptide (GIP) during a 4-week period in celiac patients on a long-term gluten-free diet. 
    The research team included Juan P Stefanolo; M...

    Jefferson Adams
    Celiac.com 09/25/2019 - Current research suggests that interleukin 15, aka IL-15, plays a key role in celiac disease. AMG 714 is the first anti-IL-15 monoclonal antibody to be assessed as a potential treatment for celiac disease. A new study looks at safety and efficacy of AMG 714 in adults with celiac disease exposed to gluten challenge.
    A team of researchers recently set out examine the effects of AMG 714 in celiac patients who underwent a gluten challenge. The research team included Marja-Leena Lähdeaho, MD, Prof Mika Scheinin, MD, Pekka Vuotikka, MD, Juha Taavela, MD, Alina Popp, MD, Johanna Laukkarinen, MD, Jukka Koffert, MD, Olli-Pekka Koivurova,...

    Jefferson Adams
    Celiac.com 02/19/2020 - What role, if any, do nutrients play in non-responsive celiac disease?
    A team of researchers recently set out to compile an overview of the causes of non-responsive celiac disease (NRCD) in adults, highlight a systematic approach to investigate these patients, and assess the latest approaches to managing this subset of celiac disease. 
    The team included Hugo A. Penny, Elisabeth M. R. Baggus, Anupam Rej, John A. Snowden, and David S. Sanders. They are variously associated with the Academic Unit of Gastroenterology, University of Sheffield, Sheffield, UK; the Lydia Becker Institute of Inflammation and Immunology, University ...